We published in 2015 and 2016 results of two sister phase 2 studies evaluating anastrozole and fulvestrant as NET in postmenopausal HR+/HER2- breast cancer patients (CARMINA02 NCT00629616; HORGEN NCT00871858).6,11 Population and design of both studies were similar. Here, ERBB2 is linked to breast cancer.